CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026GlobeNewsWire · 2 days ago
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock DropPRNewsWire · Oct 1, 2026
CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026GlobeNewsWire · Sep 29, 2026
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock DropGlobeNewsWire · Sep 23, 2026
CVRx Appoints John Landry as Chief Financial OfficerGlobeNewsWire · Sep 21, 2026
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock DropPRNewsWire · Sep 10, 2026CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.52 | -$0.53 | Miss |
| May 11, 2026 | -$0.51 | -$0.50 | Beat |
| Feb 12, 2026 | -$0.42 | -$0.46 | Miss |
| Nov 5, 2025 | -$0.50 | -$0.49 | Beat |
| Aug 4, 2025 | -$0.52 | -$0.57 | Miss |
| May 8, 2025 | -$0.56 | -$0.53 | Beat |